Pyrazolyl compounds as KV7 channel activators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new and selective Kv7 channel openers to effectively treat a variety of medical conditions, as existing compounds like ezogabine have untoward side effects and complex interaction profiles that are not well understood.
Innovation Solution
Development of pyrazolylacetamides that act as potent activators for Kv7.2/7.3 heterotetramers, with reduced side effects and improved stability, selectively modulating Kv7 channels without affecting GABAA receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ezogabine is used as a Kv7 channel opener, then channel current is significantly increased, but untoward side effects occur and the interaction profile is complex
Solution Approach 1:
The patent modifies the chemical structure of Kv7 channel openers by changing molecular parameters - specifically incorporating pyrazolyl acetamide compounds with defined substituents (R1-R6 groups) to alter the pharmacological profile. This structural parameter change achieves potent channel activation while reducing side effects and simplifying the interaction profile compared to ezogabine.
Solution Approach 2:
The patent achieves selective modulation of Kv7 channels by designing compounds with specific local chemical features - the pyrazolyl acetamide core with particular substituent patterns (where R1-R6 are defined groups) creates local molecular properties that confer selective Kv7 activity without affecting other targets like GABAA receptors, thereby reducing side effects.
2Reliability
If ezogabine is used to activate Kv7 channels, then macroscopic current amplitude increases, but the mode of action is complex and not well understood
Solution Approach 1:
The patent extracts and clarifies the mode of action by designing a series of related pyrazolyl acetamide compounds that share a common structural scaffold. This allows systematic analysis of structure-activity relationships, separating the essential pharmacological features from confounding variables, thereby improving understanding of how these compounds activate Kv7 channels and when they may exert inhibitory effects at higher voltages.
3Object-affected harmful factors
If new selective Kv7 channel openers are developed, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent segments the molecular structure into a core pyrazolyl acetamide scaffold with defined substituent positions (R1-R6). This segmentation allows independent optimization of different regions - the core provides the essential Kv7 activation pharmacology, while substituents can be adjusted to fine-tune potency, selectivity, and pharmacokinetic properties, achieving side effect reduction without excessive overall complexity.
Data Source
AI summary
Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.